Spark Therapeutics
Financials
Estimates*
EUR | 2016 | 2017 | 2018 |
---|---|---|---|
R&D budget | 82.0m | 96.0m | 109m |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
$50.0m | Series A | ||
$72.8m | Series B | ||
N/A | €161m Valuation: €352m | IPO | |
* | N/A | $133m | Post IPO Equity |
* | N/A | $128m | Post IPO Equity |
* | N/A | $380m | Post IPO Equity |
* | $4.3b Valuation: $4.3b | Acquisition | |
Total Funding | €112m |
Recent News about Spark Therapeutics
EditSpark Therapeutics is a leading biotechnology company specializing in gene therapy solutions aimed at treating genetic diseases. The company operates in the healthcare and biotechnology market, focusing on developing transformative treatments that address the underlying causes of genetic disorders. Spark Therapeutics serves a diverse range of clients, including healthcare providers, patients, and research institutions. The business model revolves around research and development (R&D), clinical trials, and commercialization of gene therapy products. Revenue is generated through product sales, partnerships, and licensing agreements. Spark Therapeutics is committed to innovation and improving patient outcomes through cutting-edge gene therapy techniques.
Keywords: gene therapy, genetic diseases, biotechnology, healthcare, R&D, clinical trials, transformative treatments, innovation, patient outcomes, commercialization.